Clopidogrel

Chemical name

Метил-(+)-(S)-альфа-(о-хло рфенил)-6,7-дигидротиен о[3.2-c]пиридин-5(4Н)-ацет��т

Gross

C16-H16-Cl-N-O2-S

Of drugs

The drugs-antiagregatine. Yes and irreversibly blocking ATP binding with the receptors platelets, strangling them activation, reduces the number of active Adf-retseptorov (without damage), prevents sorption fibrinoguena and ingibiruet agregatia Trombozitov.pri ingestion rapidly absorbed, high biodostupnostthew. Time to C_max is about 1 h. Is prolekarstvom, biotransformiroetsa in liver education metabolita active. T_1/2 about 8 am Return with urine and фекалиями.Ингибирова��ие aggregation begins after 2 h after administration (40% inhibition), registered an initial dose of 400 mg. The maximum effect (60% suppression of aggregation) is a 4-7 days of admission to the dose of 50 mg / sut. Antiagregazionny effect of a full period of nine (7-10 days). If ateroskleroticski defeat receptacle impedes development aterotromboza, regardless of the nature of the vascular (cerebrovascular, cardiovascular and peripheral defeat). When treating klopidogrelem versus aspirin relative total ishemicski risk of stroke, myocardial infarction, and vascular death is reduced by 8.7%.

Indications

Prevention of ischaemic disorders (myocardial infarction, ischemic stroke, peripheral pulmonary arteries) in patients with atherosclerosis.

Restrictions on the use of

Age 18 (safety and efficacy of the application of non-identified).

Pregnancy and lactation

Assign only as a last resort.

Contraindications

Hypersensitivity, active bleeding, severe liver disease, saying the disease stomach and duodenal ulcer.

Side-Effects

There diarrhoea phenomenon, diarrhoea, gastrointestinal bleeding, vnutricerepnae haemorrhage, neutropenia, skin skin.

Patient interaction

Potenziruet of acetylsalicylic acid on agregatia platelets, inducyrovannuu collagen. It increases the risk of gastrointestinal bleeding against the backdrop NPVS.

Precautions

Be wary appoint patients with increased risk of bleeding (trauma, surgery, koagulopatia etc.). When treating patients with serious liver should take into account the possibility of bloody diateza.

Dosing and Administration

Inside, in the 75 mg once a day, regardless of the meal. Treatment should begin within the time frame from a few days to 35 days in patients after myocardial infarction, and from 7 days to 6 months in patients after ishemicski stroke.

Literature

1. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) / / Lancet .- 1996 .- V. 348-P. 1329-1339.2. Jauahr R., Savino S., E. Deutsch et al. Aspirin and clopidogrel combination therapy in coronary stenting : a prospective registry. Abstract TCT-262 / / Am. J. Cardiol 1998 .- .- V. 82 (suppl.7A) .- P. 96.

Directory → Gematotropona funds → Antiagreganta → Clopidogrel